To further expand trading opportunities and enhance your Futures trading experience, MEXC will launch BNTX, GLXY, PURR and EL Stock Futures on the Futures market. These new listings offer a flexible and efficient way to gain exposure to some of the most prominent equities. Futures trading will be available immediately upon listing, with Futures Grid Bot strategies available within 5 minutes of listing.
Futures Trading Details
Feature | Details | Details | Details | Details |
Trading Pair | BNTXUSDT | GLXYUSDT | PURRUSDT | ELUSDT |
Listing Time | Aug 21, 2026, 11:30 (UTC) | Aug 21, 2026, 11:30 (UTC) | Aug 21, 2026, 11:30 (UTC) | Aug 21, 2026, 11:30 (UTC) |
Max Leverage | 20x | 20x | 20x | 20x |
Margin Mode | Cross & Isolated | Cross & Isolated | Cross & Isolated | Cross & Isolated |
Trading Hours | 24/7 | 24/7 | 24/7 | 24/7 |
Introduction
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma.
Galaxy Digital Inc. engages in the digital asset and data centre infrastructure businesses in North America and internationally. It operates through Digital Assets, Data Centers, and Treasury and Corporate segments. The Digital Assets segment provides over-the-counter spot and derivatives trading, lending, and structured products, as well as mergers and acquisitions advisory, and equity and debt capital markets services.
Hyperliquid Strategies Inc. operates as a digital asset treasury company focused on the blockchain and cryptocurrency sector. The company provides investors exposure to the HYPE token through treasury management strategies, such as token accumulation, staking, and yield optimization within the Hyperliquid ecosystem. The company was incorporated in 2025 and is based in New York, New York.
The Estée Lauder Companies Inc. manufactures, markets, and sells skin care, makeup, fragrance, and hair care products worldwide. The company offers skin care products, including moisturizers, serums, cleansers, toners, eye care, body care, exfoliators, acne care and oil correctors, facial masks, and sun care products; and makeup products, such as foundations, powders, concealers and setting sprays, lipsticks, lip liners and lip glosses, mascaras, and eyeshadows and eyeliners, as well as compacts, brushes, and other makeup tools. It also provides fragrance products in various forms comprising parfum, eau de parfum, eau de toilette, eau de cologne, and body spray, as well as lotions, creams, powders, candles and soaps; and hair care products, including shampoos, conditioners, styling products, treatment, finishing sprays, and hair colour products, as well as sells ancillary products and services.
